

Expression Patterns of Carbonic Anhydrase IX and Immune Response Biomarkers in Pediatric Gliomas and Glioneuronal Tumors

Journal of Neuro-Oncology

Monika Kapitančukė¹, Donatas Petroška², Agnė Petrošiūtė³, Asta Lučiūnaitė³, Švitrigailė Grincevičienė³, Daumantas Matulis³, Saulius Ročka¹, Ramūnas Raugalas¹, Dainius Rinkevičius¹, Irena Adomaitienė⁴, Gabrielė Tarutytė⁵, Jelena Rascon¹

¹ Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

² National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

³ Life Sciences Center, Vilnius University, Vilnius, Lithuania

⁴ Center of Radiology, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

⁵ Department of Research and Innovation, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Corresponding author:

Monika Kapitančukė

Center of Pediatric Oncology and Hematology

Vilnius University Hospital Santaros Klinikos

Santariskiu 7, LT-08406

Vilnius, Lithuania

E-mail: monika.kapitancuke@santa.lt

SI3. EFS probability by tumor characteristics and biomarker expression

Characteristic	EFS probability at 2 years (%)	95% CI
CNS WHO Grade 1–2	84.5	71.7–99.7
CNS WHO Grade 3–4	14.3	2.3–87.7
Tumor GTR	82.4	66.1–100.0
Tumor Bx/PR	55.3	35.2–86.9
CAIX ≤30 H-score	65.4	49.4–86.5
CAIX >30 H-score	83.3	58.3–100.0
CD3 ≤5%	68.5	53.4–87.9
CD3 >5%	66.7	30.0–100.0
CD8 ≤5%	67.2	52.4–86.2
CD8 >5%	100.0	100.0–100.0
CD44 ≤200 H-score	61.9	44.3–86.6
CD44 >200 H-score	80.0	58.7–100.0
CD68 ≤30%	53.8	35.6–81.4
CD68 >30%	91.7	77.3–100.0
CD163 ≤30%	68.4	53.2–87.8
CD163 >30%	75.0	42.6–100.0
PD-L1 ≤5%	70.5	56.0–88.7
PD-L1 >5%	-	-
CD206 ≤5%	70.0	55.3–88.6
CD206 >5%	-	-
CCR2 ≤30%	64.9	49.5–85.1
CCR2 >30%	100.0	100.0–100.0

Abbreviations: Bx, biopsy; CNS, central nervous system; EFS, event-free survival; GTR, gross total resection; PR, partial resection; WHO, World Health Organization.